Content about Piperazines

November 29, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

Watson to change brand in 2013
PARSIPPANY, N.J. — Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said. Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission in October, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.


November 29, 2012

In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


November 13, 2012

The Food and Drug Administration has approved a generic drug made by Mylan for treating pulmonary arterial hypertension, the drug maker said Tuesday.

PITTSBURGH — The Food and Drug Administration has approved a generic drug made by Mylan for treating pulmonary arterial hypertension, the drug maker said Tuesday.

Mylan announced the FDA approval of sildenafil citrate tablets in the 20-mg strength, a generic version of Pfizer's Revatio. The drug is used to treat adults with PAH to improve exercise ability and delay clinical worsening of the condition.

Revatio had sales of about $339 million during the 12-month period ended in September, according to IMS Health.

November 12, 2012

The Food and Drug Administration has approved a generic drug for pulmonary arterial hypertension made by Watson Pharmaceuticals, the drug maker said Monday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug for pulmonary arterial hypertension made by Watson Pharmaceuticals, the drug maker said Monday.

Watson said the FDA approved its sildenafil tablets in the 20 mg strength through a subsidiary. Watson said it would launch the drug "in the near future."

The drug is a generic version of Pfizer's Revatio tablets, which had sales of about $339 million during the 12-month period ended in September, according to IMS Health.

October 29, 2012

Par Pharmaceutical Cos. has bought rights to a generic version of a drug used to treat bipolar disorder and schizophrenia.

WOODCLIFF LAKE, N.J. – Par Pharmaceutical Cos. has bought rights to a generic version of a drug used to treat bipolar disorder and schizophrenia.

October 26, 2012

The Food and Drug Administration has approved what it called the second new drug in two months for a form of leukemia, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved what it called the second new drug in two months for a form of leukemia, the agency said Friday.

The FDA announced the approval of Teva Pharmaceutical Industries' Synribo (omacetaxine mepesuccinate) for chronic myelogenous leukemia, or CML, a disease that the National Institutes of Health expects will be diagnosed in more than 5,400 people this year. The drug is intended for patients whose disease has progressed after treatment with at least two drugs of a class used to treat the disease.

October 2, 2012

Drug makers Takeda Pharmaceutical and H. Lundbeck have applied with the Food and Drug Administration for a new drug to treat depression in adults.

OSAKA, Japan — Drug makers Takeda Pharmaceutical and H. Lundbeck have applied with the Food and Drug Administration for a new drug to treat depression in adults.

Japan-based Takeda and Denmark-based Lundbeck announced the submission of a new drug application for Lu AA21004 (vortioxetine) for major depressive disorder.

September 21, 2012

The Food and Drug Administration has approved a generic drug for motion sickness made by Mylan.

PITTSBURGH — The Food and Drug Administration has approved a generic drug for motion sickness made by Mylan.

The drug maker announced Friday that the FDA had approved meclizine hydrochloride tablets in the 12.5-mg, 25-mg and 50-mg strengths. Mylan said it would launch the drug immediately.

The drug is a generic version of Pfizer's Antivert, which is used to treat nausea, vomiting and dizziness associated with motion sickness. Antivert had sales of about $53.5 million during the 12-month period ended in June, according to IMS Health.

September 11, 2012

The Food and Drug Administration on Thursday issued warning letters to PruTect Rx, of Highlands Ranch, Colo., and Trinity Sports Group, of Plano, Texas, for promoting products labeled as dietary supplements with claims to treat concussions and prevent or treat post-concussion syndrome and other neurological disorders.

SILVER SPRING, Md. — The Food and Drug Administration on Thursday issued warning letters to PruTect Rx, of Highlands Ranch, Colo., and Trinity Sports Group, of Plano, Texas, for promoting products labeled as dietary supplements with claims to treat concussions and prevent or treat post-concussion syndrome and other neurological disorders.

September 5, 2012

The Food and Drug Administration has approved a new drug for treating a rare blood and marrow cancer that affects older adults, the agency said Tuesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a rare blood and marrow cancer that affects older adults, the agency said Tuesday.

The FDA announced the approval of Pfizer's Bosulif (bosutinib) for chronic myelogenous leukemia, or CML. According to the FDA, about 5,430 men and women will be diagnosed with CML this year.

The drug is designed for patients with chronic, accelerated or blast-phase Philadelphia chromosome-positive CML, who can't tolerate other therapies or for whom those therapies don't work.

August 23, 2012

Indian drug maker Wockhardt has received tentative approval from the Food and Drug Administration for a generic version of a Pfizer psychiatric drug.

PARSIPPANY, N.J. — Indian drug maker Wockhardt has received tentative approval from the Food and Drug Administration for a generic version of a Pfizer psychiatric drug.

Wockhardt announced the tentative approval for ziprasidone hydrochloride in the 20 mg, 40 mg, 60 mg and 80 mg strengths, used to treat bipolar disorder and schizophrenia, and the company plans to launch the drug on Sept. 2, 2012.

June 18, 2012

Greenstone, the generic pharmaceutical subsidiary of Pfizer, has launched olanzapine tablets.

PEAPACK, N.J. — Greenstone, the generic pharmaceutical subsidiary of Pfizer, has launched olanzapine tablets.

The drug, which is a generic version of Zyprexa — an Eli Lilly drug used to treat psychiatric disorders — in the 2.5-mg, 5-mg, 7.5-mg, 10-mg, 15-mg and 20-mg strengths.

Generic and branded versions of the drug had sales of about $3.28 billion during the 12-month period ended in January, according to IMS Health.

June 4, 2012

An experimental drug made by Bayer HealthCare extended the length of time that patients with gastrointestinal tumors survived without their disease getting worse, according to results of a late-stage clinical trial released Monday.

WAYNE, N.J. — An experimental drug made by Bayer HealthCare extended the length of time that patients with gastrointestinal tumors survived without their disease getting worse, according to results of a late-stage clinical trial released Monday.

April 25, 2012

Sun Pharmaceutical Industries has launched a generic version of a drug used to treat psychiatric disorders, the company said.

MUMBAI, India — Sun Pharmaceutical Industries has launched a generic version of a drug used to treat psychiatric disorders, the company said.

Sun announced the launch of olanzapine tablets in the 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths.

The drug is a generic version of Eli Lilly's Zyprexa, used to treat schizophrenia and bipolar disorder. The branded drug and generic versions had sales of $3.28 billion during the 12-month period ended in January, according to IMS Health.

 

April 24, 2012

Mylan has launched a generic drug for treating psychiatric disorders, the company said Tuesday.

PITTSBURGH — Mylan has launched a generic drug for treating psychiatric disorders, the company said Tuesday.

Mylan announced the launch of olanzapine tablets in the 2.5-mg, 5-mg, 7.5-mg, 10-mg, 15-mg and 20-mg strengths.

The drug, a generic version of Eli Lilly's Zyprexa, is used to treat schizophrenia and bipolar disorder. Various versions of the drug had sales of about $3.3 billion in 2011, according to IMS Health.

March 5, 2012

Indian drug maker Dr. Reddy's has launched a drug designed to treat bipolar disorder and schizophrenia, the company said.

HYDERABAD, India — Indian drug maker Dr. Reddy's has launched a drug designed to treat bipolar disorder and schizophrenia, the company said.

The company announced the launch of ziprasidone hydrochloride capsules in the 20-mg, 40-mg, 60-mg and 80-mg strengths.

The drug is a generic version of Pfizer's Geodon, which had sales of $1.34 billion in 2011, according to IMS Health.

February 3, 2012

Teva Pharmaceuticals has launched a generic version of a psychiatric drug, the company said Friday.

NORTH WALES, Pa. — Teva Pharmaceuticals has launched a generic version of a psychiatric drug, the company said Friday.

Teva announced the launch of olanzapine orally disintegrating tablets in the 5-mg, 10-mg, 15-mg and 20-mg strengths in blister packs of 30.

The drug is a generic version of Eli Lilly's Zyprexa Zydis, used to treat schizophrenia and bipolar disorder.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

December 20, 2011

Specialty pharmacy provider The Apothecary Shops is encouraging medication adherence with a cap for pill containers that cues patients with lights and sounds, the company said.

PHOENIX — Specialty pharmacy provider The Apothecary Shops is encouraging medication adherence with a cap for pill containers that cues patients with lights and sounds, the company said.

December 14, 2011

A Food and Drug Administration panel has voted to recommend approval for a psychiatric drug made by Alexza Pharmaceuticals.

MOUNTAIN VIEW, Calif. — A Food and Drug Administration panel has voted to recommend approval for a psychiatric drug made by Alexza Pharmaceuticals.

October 24, 2011

The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

The FDA announced the approval of generic olanzapine tablets and olanzapine orally disintegrating tablets, respectively generic versions of Lilly's Zyprexa and Zyprexa Zydus. Dr. Reddy's Labs and Teva Pharmaceuticals USA will manufacture olanzapine tablets, while Dr. Reddy's, Apotex and Par Pharmaceuticals will manufacture the orally disintegrating version.

September 28, 2011

A new report from the Department of Health and Human Services' Agency for Healthcare Research and Quality found little evidence to support the use of atypical antipsychotic drugs for uses other than those for which they have official approval.

ROCKVILLE, Md. — A new report from the Department of Health and Human Services' Agency for Healthcare Research and Quality found little evidence to support the use of atypical antipsychotic drugs for uses other than those for which they have official approval.

August 30, 2011

The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

ALLEGAN, Mich. — The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

The drug maker said Tuesday that the FDA approved ketoconazole foam in the 2% strength. The drug is a generic version of Stiefel Labs' Extina, a topical drug used to treat seborrheic dermatitis in patients ages 12 years and older with healthy immune systems.

Extina has annual sales of about $10 million, according to Perrigo.

August 18, 2011

Sato Pharmaceutical on Wednesday launched Zentrip, a new motion-sickness product featuring a fast-dissolving, fast-acting, citrus-flavored meclizine hydrochloride thin-strip.

TORRANCE, Calif. — Sato Pharmaceutical on Wednesday launched Zentrip, a new motion-sickness product featuring a fast-dissolving, fast-acting, citrus-flavored meclizine hydrochloride thin-strip.

May 24, 2011

The Food and Drug Administration has approved a generic over-the-counter treatment for allergies made by Taro Pharmaceutical Industries.

HAWTHORNE, N.Y. — The Food and Drug Administration has approved a generic over-the-counter treatment for allergies made by Taro Pharmaceutical Industries.

Taro announced Monday the approval of cetirizine hydrochloride oral solution.

The drug, a generic version of Johnson & Johnson’s children’s Zyrtec, is used to relieve symptoms of indoor and outdoor allergies and is available in a sugar-free bubblegum flavor.

May 18, 2011

Cancer drugs are expected to see sharp increases in spending and use by 2013, according to the latest drug trend report by pharmacy benefit manager Medco Health Solutions.

ORLANDO, Fla. — Cancer drugs are expected to see sharp increases in spending and use by 2013, according to the latest drug trend report by pharmacy benefit manager Medco Health Solutions.

The overall drug trend for 2010 was 3.7%, lowered by higher rates of generic drug dispensing; more than 71% of drugs dispensed were generics. Specialty drugs, mostly branded biologics, accounted for 70.1% of the overall drug trend, with especially strong growth in cancer drugs, whose drug trend reached 21.2%.